Home / Guides / Will tirzepatide get cheaper?

What’s changed. What’s next.

Will tirzepatide get cheaper? What’s changed in 2026 and what’s scheduled for 2027

By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated

Tirzepatide already got cheaper: Zepbound fell to $299–$449 a month at LillyDirect in December 2025, with no new cut announced as of November 1, 2026. LillyDirect’s $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide at NexLife is $139 a month on the 12-month plan, or $169 month to month, the same at every dose.

$139/mo on 12 months, every dosePrice Match Guarantee†

  • December 1, 2025: Zepbound vials cut to $299–$449 a month ($449 from 7.5 mg needs a refill within 45 days; otherwise $499–$699)
  • December 31, 2026: temporary Foundayo and Wegovy prices end
  • Main tirzepatide patent: listed through May 13, 2036
Published by NexLifeLegitScript-certifiedUpdated By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043)
NexLifeSame price at every dose
Illustration of a compounded tirzepatide vial

$139/mo on a 12-month plan, all-inclusive, same price at every dose

Or $169/mo month to month

Brand-name Zepbound: $299 to $449 a month at LillyDirect, by dose; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699

Check my eligibility

About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication

See all 4 plans and what a year costs
Compounded tirzepatide, all in, the same price at every dose
PlanPer month12 months at this rate
12-month Lowest monthly price$139$1,668
6-month$149$1,788
3-month$159$1,908
Month to month$169$2,028

Month to month costs $360 more over 12 months than the 12-month plan. Plans renew until you cancel. Longer plans bill the way you choose at checkout.

Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works

Call (949) 818-8000Text us

4.8 out of 5 on Trustpilot, 407 reviewsLegitScript-certified

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.

  • Licensed U.S. providers
  • LegitScript certified
  • Free expedited shipping
  • HSA, FSA, Affirm, Klarna, Afterpay
  • 24/7 support, real people
  • Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)

Will tirzepatide and Zepbound get cheaper?

Will tirzepatide get cheaper? Six questions and their answers, as of November 1, 2026
QuestionAnswer
Has tirzepatide gotten cheaper?Yes. Lilly cut Zepbound vials on December 1, 2025. At LillyDirect, Zepbound now starts at $299 a month (checked November 1, 2026).
Is another cut announced?No. Lilly hasn’t announced a new Zepbound price, as of November 1, 2026.
What ends December 31, 2026?Lilly’s Zepbound savings cards, Foundayo’s reduced 2.5 mg and 5.5 mg prices, and Wegovy’s $199 price for each of a new patient’s first two fills.
What about Medicare?The GLP-1 Bridge: $50 a month for the Zepbound KwikPen, Wegovy or Foundayo, if you qualify. It’s set to end December 31, 2027.
Will Medicare negotiate tirzepatide’s price?Not so far. It isn’t on CMS’s negotiation lists for 2027 or 2028.
What does compounded tirzepatide cost?In our price index, $139 to $399 month to month, all in (median $237, checked November 1, 2026). It isn’t FDA-approved. At NexLife: $139 a month on the 12-month plan.
  1. Tell us about you About 3 minutes of health questions
  2. A licensed provider decides You’re prescribed only if it’s right for you
  3. Your partner pharmacy ships Usually within 1 to 2 business days, free

Key takeaways

  • It already did: Lilly cut Zepbound vials on December 1, 2025; they start at $299 at LillyDirect (checked November 1, 2026).
  • No new cut is announced. LillyDirect’s $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699.
  • Watch December 31, 2026: Lilly’s Zepbound savings cards, Foundayo’s reduced prices and Wegovy’s $199 price for each of a new patient’s first two fills end.
  • Medicare’s GLP-1 Bridge: people with Part D who qualify pay $50 a month, through December 31, 2027.
  • 2027’s announced changes are mostly for semaglutide. Tirzepatide isn’t on Medicare’s negotiation lists for 2027 or 2028.
  • At NexLife, compounded tirzepatide is $139 a month on the 12-month plan, or $169 month to month, at every dose.
NexLife

Not waiting for a price cut? Compounded tirzepatide at NexLife: $139/mo on 12 months, $169 month to month, every dose.About 3 minutes of health questions, no insurance needed. Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you.

Check my eligibility

Prices today

Which tirzepatide prices change next?

At LillyDirect, Zepbound is $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg to 15 mg (checked November 1, 2026). The $449 needs a refill within 45 days, or it’s $499 to $699. No new Lilly cut is announced. The next dated change is December 31, 2026, when Lilly’s Zepbound savings cards end. LillyDirect’s own prices list no end date.

Each maker’s self-pay prices and TrumpRx.gov’s listings, checked November 1, 2026: the medication alone, with your prescriber’s visit extra. A Zepbound month is 28 days. Medicare figures from CMS and KFF. Compounded prices from our GLP-1 price index, checked November 1, 2026. “Next dated change” is the next change a maker or agency has announced, as of November 1, 2026.
Medicine, and where you buy itPrice todayNext dated change
Zepbound KwikPen or vialstirzepatide; LillyDirect, self-pay$299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg to 15 mg with a refill within 45 days ($499 to $699 if not)None announced for LillyDirect’s prices. Lilly’s savings cards, including the KwikPen card for retail pharmacies, end December 31, 2026
Zepbound on TrumpRx.gova government price listingStarting at $299, the same starting price as LillyDirectNone announced. Vial orders go through LillyDirect
Mounjarotirzepatide for type 2 diabetes; LillyDirect, self-pay$499 at every doseNone announced
Medicare GLP-1 BridgeZepbound KwikPen, Wegovy or Foundayo, if you qualify$50 a month. Medicare’s net price: $245Set to end December 31, 2027
Foundayo pillorforglipron; LillyDirect, self-pay$149 at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 from 9 mgThe 2.5 mg and 5.5 mg prices are reduced through December 31, 2026. TrumpRx.gov lists their regular prices as $199 and $299
Wegovy pensemaglutide; NovoCare, self-pay$349, or $399 for Wegovy HD 7.2 mg. New patients: $199 for each of their first 2 fills at 0.25 or 0.5 mgThe $199 offer ends December 31, 2026. The list price falls to $675 on January 1, 2027; Novo says self-pay prices don’t change
Wegovy pillsemaglutide; NovoCare, self-pay$149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg or 25 mgThe list price falls to $675 on January 1, 2027
Compounded tirzepatideonline programs; not FDA-approved$139 to $399 a month, all in (median $237 across 14 programs, checked November 1, 2026)Each program sets its own. Our index logs every re-check with its date

NexLife Price Match Guarantee†. Already on compounded tirzepatide with another licensed provider, and paying less? We match your regular monthly price. How it works

Swipe the table sideways to see every column.

Each maker’s self-pay prices and TrumpRx.gov’s listings, checked November 1, 2026: the medication alone, with your prescriber’s visit extra. A Zepbound month is 28 days. Medicare figures from CMS and KFF. Compounded prices from our GLP-1 price index, checked November 1, 2026. “Next dated change” is the next change a maker or agency has announced, as of November 1, 2026.

Step by step

How do you pay less for tirzepatide now, step by step?

No new Zepbound cut is announced as of November 1, 2026. Here’s how to pay less at today’s prices.

  1. Price your dose at LillyDirect. Zepbound is $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 to 15 mg with a refill within 45 days ($499 to $699 if not). TrumpRx.gov lists the same $299 start.
  2. Mark December 31, 2026. Lilly’s Zepbound savings cards, Foundayo’s reduced 2.5 mg and 5.5 mg prices and Wegovy’s $199 price for each of a new patient’s first two fills end that day. LillyDirect’s own self-pay prices list no end date.
  3. On Medicare, check the Bridge. People with Part D who qualify pay $50 a month for the Zepbound KwikPen, Wegovy or Foundayo. The Bridge is set to end December 31, 2027.
  4. Compare compounded prices. Compounded tirzepatide, which isn’t FDA-approved, is $139 to $399 a month online in our price index, all in (median $237). Lilly’s and Novo’s cuts don’t set these prices; each program sets its own.
  5. Pick your plan length. At NexLife, compounded tirzepatide is $139 a month on the 12-month plan or $169 month to month, the same at every dose. Paying less elsewhere? Our Price Match Guarantee† matches your regular monthly price.

We list only announced, dated changes; we don’t forecast prices.

Timeline

What changed, and when? GLP-1 prices since November 2025

Since November 2025, Zepbound’s and Wegovy’s self-pay prices have both dropped. Novo cut Wegovy from $499 to $349 a month on November 17, 2025, and Lilly cut Zepbound vials to $299–$449 on December 1, 2025. Zepbound’s $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Medicare’s $50 GLP-1 Bridge began July 1, 2026. Each dated change is below, with its source at the end of the page.

  1. The White House announces deals with Lilly and Novo Nordisk. Zepbound and orforglipron, if approved, were announced to average $346 a month through TrumpRx, down from $1,086. Medicare’s price for Zepbound, Mounjaro, Wegovy and Ozempic: $245, with a $50 copay.

  2. Novo Nordisk cuts Wegovy’s self-pay price from $499 to $349 a month, and offers new patients $199 for each of their first two fills (through Dec. 31, 2026).

  3. Lilly cuts Zepbound vials on LillyDirect: 2.5 mg from $349 to $299, 5 mg from $499 to $399, and 7.5 mg to 15 mg from $499 to $449 with a refill within 45 days.

  4. The Wegovy pill, approved December 22, 2025, goes on sale at $149 a month for the starting dose.

  5. The Zepbound KwikPen arrives at the same self-pay prices as the vials, starting at $299.

  6. Novo Nordisk says the list price of Wegovy, Ozempic and Rybelsus will fall to $675 a month on January 1, 2027, about 50% off Wegovy’s list price at the time.

  7. The FDA approves Foundayo, Lilly’s daily GLP-1 pill. Self-pay starts at $149 a month for the lowest dose.

  8. CMS says its BALANCE Model won’t start in Medicare in 2027, and extends the Medicare GLP-1 Bridge through 2027.

  9. Medicare’s GLP-1 Bridge begins: $50 a month for the Zepbound KwikPen, Wegovy or Foundayo, for people with Part D who qualify.

Prices are the makers’ self-pay prices for the medication alone. Your prescriber’s visit is extra. For today’s Zepbound prices dose by dose, and a year’s total, see Zepbound cost without insurance.

TrumpRx

What do Zepbound, Wegovy and Foundayo cost on TrumpRx?

The same as buying from the maker. On TrumpRx.gov, checked November 1, 2026, Zepbound starts at $299, the Wegovy pen at $199 for each of a new patient’s first two fills (through Dec. 31, 2026) and the Wegovy pill at $149. Foundayo shows “up to 77% off,” by dose. TrumpRx lists each maker’s self-pay price, then sends you to the maker or gives you a coupon.

TrumpRx.gov listings, checked November 1, 2026. TrumpRx links you to the maker’s pharmacy or gives you a coupon; every price is self-pay.
On TrumpRx.govListed priceHow you buyGood to know
Zepbound vialsLillyStarting at $299Through LillyDirect“Up to 72% off,” with no original price shown (checked November 1, 2026)
Zepbound KwikPenLillyStarting at $299LillyDirect, or a retail pharmacy it transfers toThe same starting price as LillyDirect
FoundayoLillyUp to 77% off, by doseLillyDirect, or a retail pharmacy it transfers to2.5 mg and 5.5 mg reduced through December 31, 2026; regular prices $199 and $299
Wegovy penNovo NordiskStarting at $199A coupon you show at a pharmacy$199 for each of a new patient’s first 2 fills through December 31, 2026, then $349 ($399 at 7.2 mg)
Wegovy pillNovo NordiskStarting at $149A coupon you show at a pharmacyShown against an original price of $1,349.02

Swipe the table sideways to see every column.

TrumpRx.gov listings, checked November 1, 2026. TrumpRx links you to the maker’s pharmacy or gives you a coupon; every price is self-pay.

“The price of Zepbound and Orforglipron, if approved, will fall from $1,086 per month to an average of $346 when purchased through TrumpRx.”

The White House, Fact sheet on Most-Favored-Nation pricing, November 6, 2025

Is TrumpRx cheaper than LillyDirect? Not at the starting dose: both list Zepbound at $299, and TrumpRx sends vial orders to LillyDirect.

Have insurance or Medicare? TrumpRx prices are for paying yourself. Its Wegovy terms say you can’t bill that purchase to insurance or count it toward your deductible or out-of-pocket limit. On Medicare Part D, the $50 Bridge may cost less: see who qualifies.

What’s scheduled

Which GLP-1 price changes are scheduled for late 2026 and 2027?

Three dates matter most. On December 31, 2026, Foundayo’s reduced prices, Wegovy’s $199 price for each of a new patient’s first two fills and Lilly’s Zepbound savings cards end. On January 1, 2027, Wegovy’s list price falls to $675 and Medicare’s semaglutide price starts. On December 31, 2027, the Medicare GLP-1 Bridge is set to end. We list only dated, sourced changes.

  1. Last day for Foundayo’s reduced prices: $149 at 2.5 mg and $199 at 5.5 mg. TrumpRx.gov lists their regular prices as $199 and $299.

  2. Last day for Wegovy’s $199 price on each of a new patient’s first two fills at 0.25 or 0.5 mg. After that, Novo’s pen price is $349, or $399 for Wegovy HD 7.2 mg.

  3. Lilly’s Zepbound savings cards expire, their terms say. That includes the card that brings the KwikPen’s self-pay prices to retail pharmacies. LillyDirect’s own self-pay prices list no end date.

  4. Novo Nordisk’s list price for Wegovy, Ozempic and Rybelsus falls to $675 a month. Novo says its self-pay prices don’t change.

  5. Medicare’s negotiated price for semaglutide (Ozempic, Rybelsus and Wegovy) starts: $274 for a 30-day supply, against a 2024 list price of $959.

  6. Lilly plans to submit retatrutide to the FDA. It isn’t approved, and Lilly says it can’t legally be sold.

  7. An FDA exclusivity for tirzepatide as a new chemical entity ends, the Orange Book shows. Its main patent is listed through May 13, 2036.

  8. Medicare’s GLP-1 Bridge is set to end. CMS calls bringing its BALANCE Model to Part D a “potential” next step; no 2028 plan is announced.

Not announced, as of November 1, 2026

  • A new Zepbound price for 2027, at LillyDirect or on TrumpRx.gov.
  • A Medicare negotiated price for tirzepatide. It isn’t on CMS’s lists for 2027 or 2028.
  • A tirzepatide generic. Its listed patents run through May 13, 2036 and later.
  • U.S. prices for retatrutide or CagriSema. Neither is FDA-approved.
  • Medicare coverage for weight loss after December 31, 2027.

In their words

What do CMS and the FDA say about future tirzepatide costs?

Three lines behind this page’s dates: when the Bridge ends, what Medicare covers, and what can’t be compounded.

If you qualify, the $50 Bridge costs less than paying yourself, but it’s set to end. CMS’s own description:

“The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027.”

Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge

No Medicare coverage for weight loss after December 31, 2027 is announced, as of November 1, 2026. CMS describes the usual rule for GLP-1 drugs:

“Medicare and Medicaid generally do not cover these drugs for the weight loss indication”

Centers for Medicare & Medicaid Services, BALANCE Model

Cagrilintide is one of CagriSema’s two ingredients. On it and on retatrutide, the FDA says:

“Retatrutide and cagrilintide cannot be used in compounding under federal law.”

U.S. Food and Drug Administration, FDA’s concerns with unapproved GLP-1 drugs used for weight loss, updated October 1, 2026

New drugs

Will retatrutide or CagriSema push prices down?

No one can say yet. Neither is FDA-approved, so neither has a U.S. price. Novo expects a CagriSema decision by late 2026, and Lilly plans to submit retatrutide in the first quarter of 2027. The newest approved pills, the Wegovy pill and Foundayo, start at $149 a month self-pay. Every pipeline date: new weight loss drugs 2027.

  • Retatrutide, from Lilly

    An investigational weekly shot. Lilly said on July 23, 2026 that it plans to submit it to the FDA in the first quarter of 2027. Until it’s approved, it has no price and can’t legally be sold. Retatrutide, explained.

  • CagriSema, from Novo Nordisk

    Submitted to the FDA on December 18, 2025. On February 23, 2026, Novo said it expects a decision by late 2026. It isn’t on the FDA’s list of 2026 novel drug approvals, checked November 1, 2026.

  • Two pills, already here

    The Wegovy pill went on sale January 5, 2026, and Foundayo was approved April 1, 2026. Both start at $149 a month self-pay for the lowest dose, below Zepbound’s $299. Foundayo’s cost by dose.

  • No compounded versions

    The FDA says retatrutide and cagrilintide, one of CagriSema’s two ingredients, can’t be used in compounding under federal law.

Not announced: what either new drug will cost, or whether either will change Zepbound’s price. So we don’t guess.

List price

Will a list price cut lower what you pay?

Only if your costs follow list price. Novo cuts Wegovy’s list price to $675 on January 1, 2027, which can lower coinsurance or a deductible figured on list price. A flat copay stays the same, and Novo says self-pay prices don’t change. Paying cash? Novo’s cut won’t lower your price. More: Wegovy price in 2027.

  • List price

    What the maker charges wholesalers. Lilly gives Zepbound’s as $499 to $1,086.37 per fill. Novo’s 2027 cut to $675 is a list-price cut.

  • Self-pay price

    What you pay in cash, straight from the maker: $299 to $449 a month for Zepbound at LillyDirect; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Novo says its list-price cut doesn’t change its self-pay prices.

  • Your share with insurance

    Your copay or coinsurance. Novo says a lower list price helps most where costs follow list price, as with high-deductible plans or coinsurance.

  • Net price

    What a payer ends up paying after rebates. In Medicare’s Bridge, the makers agreed to a $245 net price for a month’s supply, KFF reports, while patients pay $50.

Compounded

Do brand-name price cuts change compounded tirzepatide prices?

$139 to $399 a month online, all in, across the 14 programs in our GLP-1 price index (median $237, checked November 1, 2026). Lilly’s and Novo’s cuts don’t set these prices; each program sets its own. Nine of the 14 say their price is the same at every dose. Who charges least: cheapest tirzepatide online. Paying less elsewhere? Our Price Match Guarantee† matches your regular monthly price.

  • $237median month-to-month price, all in14 programs, checked November 1, 2026
  • 9 of 14say their price is the same at every dosethe rest rise with dose or don’t say
  • $139–$399a month online, month to monthmedication plus any required fee

Lilly’s and Novo’s price cuts don’t set these prices. Each online program sets its own, and they change program by program. Our GLP-1 price index logs every re-check with its date, newest first. Month by month and over a year: tirzepatide cost per month.

Compounded isn’t brand-name. Compounded tirzepatide isn’t Zepbound, isn’t FDA-approved and wasn’t studied in Zepbound’s trials. A provider prescribes it only when it offers a significant difference for you.

At NexLife

Not waiting for a price cut? Compounded tirzepatide at NexLife

You don’t have to wait: no new Zepbound cut is announced as of November 1, 2026, and compounded tirzepatide is prescribed today. At NexLife, its price is the same at every dose, from 2.5 mg to 15 mg, with no membership fee. It isn’t FDA-approved, and a licensed provider decides if it’s right for you.

The details
12-month plan$139 a month
6-month plan$149 a month
3-month plan$159 a month
Month to month$169 a month

The same at every dose, from 2.5 mg to 15 mg, with no membership fee. Month to month, $169 is $68 under the $237 median of the 14 tirzepatide programs in our GLP-1 price index.

Included: your licensed provider, the medication from a state-licensed 503A partner pharmacy, a nutrition plan, a 1:1 coaching call, free expedited shipping and real people 24/7.

Ways to pay: Affirm, Klarna or Afterpay at checkout, or an HSA or FSA card; NexLife provides a letter of medical necessity. With Medicare, you can pay yourself. If you qualify for the Bridge, its $50 a month costs less.

Vial math

How many units is your tirzepatide dose?

It depends on your vial’s strength. Here are the label’s doses at one example strength, with the math to check your own.

Tirzepatide doses on Zepbound’s label, with the volume and units on a U-100 syringe at an example strength of 25 mg per mL; your vial’s label decides
DosemL at 25 mg/mLUnits (U-100)On the label
2.5 mg0.1 mL10 unitsStarting dose, for 4 weeks
5 mg0.2 mL20 unitsA maintenance dose
7.5 mg0.3 mL30 unitsA step up
10 mg0.4 mL40 unitsA maintenance dose
12.5 mg0.5 mL50 unitsA step up
15 mg0.6 mL60 unitsThe maximum, and a maintenance dose

The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.

25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart.

What does NexLife cost?
One flat price at every dose.

No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†

Illustration of a compounded tirzepatide vialGIP + GLP-1

12-month plan $139/mo

Tirzepatide

Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

Illustration of a compounded semaglutide vialGLP-1

12-month plan $119/mo

Semaglutide

Weekly GLP-1. Care, coaching and shipping included. On a 12-month plan; $139/mo month to month.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms

The NexLife Price Match Guarantee†

Paying less elsewhere?
Keep your price. Upgrade your care.

Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.

  1. 1Send a receipt from the last 60 days
  2. 2A NexLife provider reviews your prescription
  3. 3Pay your matched price, at every dose
Switch and keep my price

Locked while your plan is activeSame price at every doseNo membership fee

†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.

Price changes: your questions

Fair questions about NexLife

Will my price go up with my dose?
No. You pay the same at every dose.
What if I’m not prescribed?
You aren’t charged for medication.
Can I cancel?
Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
Do I need insurance?
No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.

When will tirzepatide be cheaper?

It already is: Lilly cut Zepbound vials to $299–$449 a month at LillyDirect on December 1, 2025, and no new cut is announced as of November 1, 2026. The $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Next dated change: Lilly’s Zepbound savings cards end December 31, 2026.

Will Zepbound get cheaper in 2027?

No cut is announced: as of November 1, 2026, Lilly hasn’t announced a new Zepbound price for 2027. LillyDirect charges $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg to 15 mg with a refill within 45 days, or $499 to $699. Lilly’s savings cards expire December 31, 2026, their terms say.

What price does TrumpRx.gov list for Zepbound?

TrumpRx.gov lists Zepbound vials and the KwikPen starting at $299 a month, LillyDirect’s price for 2.5 mg, and Lilly fills vial orders through LillyDirect (checked November 1, 2026). The White House’s November 6, 2025 deal said Zepbound would average $346 a month through TrumpRx, down from $1,086.

Is TrumpRx cheaper than LillyDirect?

Not at the starting dose: TrumpRx.gov lists Zepbound at $299, the same as LillyDirect, and sends vial orders to LillyDirect (checked November 1, 2026). These are self-pay prices: the terms say you can’t bill them to insurance or count them toward a deductible. On Medicare Part D, the $50 Bridge may cost less.

When does the $149 Foundayo price end?

For the 2.5 mg dose, after December 31, 2026: Lilly says that price is temporarily reduced through then, and TrumpRx.gov lists the regular price as $199. The 5.5 mg dose’s $199 is temporary too; its regular price is $299. The 0.8 mg starting dose is also $149, and LillyDirect doesn’t mark that price as temporary (checked November 1, 2026).

Will compounded tirzepatide prices change?

They can, program by program: our GLP-1 price index logs every re-check with its date. There, the compounded tirzepatide price is $139 to $399 month to month, all in (median $237, checked November 1, 2026). At NexLife it’s $139 a month on the 12-month plan or $169 month to month, the same at every dose. It isn’t FDA-approved.

Will Medicare negotiate a lower price for tirzepatide?

No, not so far: tirzepatide isn’t on CMS’s negotiation lists for 2027 or 2028. Semaglutide is: its negotiated price, $274 for a 30-day supply, starts January 1, 2027. Under the GLP-1 Bridge, makers agreed to a $245 net price for a month’s supply, and people with Part D who qualify pay $50 a month.

When does tirzepatide’s patent expire?

The FDA’s Orange Book lists Lilly’s main tirzepatide patent, on the drug itself, through May 13, 2036 (checked October 22, 2026). Other listed patents run to July 22, 2039 for Zepbound and December 30, 2041 for Mounjaro. A separate FDA exclusivity for tirzepatide as a new chemical entity ends May 13, 2027.

Does Novo’s 2027 list price cut lower what I pay for Wegovy?

Not if you pay cash: Novo Nordisk says the $675 list price, starting January 1, 2027, doesn’t change its self-pay prices. It mainly helps people whose costs are tied to list price, such as those with high-deductible plans or coinsurance, Novo says. Today the Wegovy pen is $349 a month self-pay, or $399 for Wegovy HD 7.2 mg.

How much did Zepbound’s price drop?

On December 1, 2025, Lilly cut Zepbound vials at LillyDirect: 2.5 mg from $349 to $299, 5 mg from $499 to $399 and 7.5 mg to 15 mg from $499 to $449 with a refill within 45 days. The KwikPen later arrived at the same self-pay prices.

Will Mounjaro get cheaper?

Not that anyone has announced. At LillyDirect, Mounjaro, Lilly’s tirzepatide for type 2 diabetes, is $499 at every dose self-pay, with no price change announced (checked November 1, 2026). Tirzepatide also isn’t on CMS’s Medicare negotiation lists for 2027 or 2028.

Is Foundayo cheaper than Zepbound?

At the lowest dose, yes. Foundayo, Lilly’s daily GLP-1 pill, starts at $149 a month self-pay, below Zepbound’s $299. Its 2.5 mg and 5.5 mg prices are reduced through December 31, 2026; TrumpRx.gov lists their regular prices as $199 and $299.

Important safety information

Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Read the full safety information

In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other GLP-1 medicines.

Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.

This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.

About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.

Who wrote and medically reviewed this page?

Adam Kennah, MDMedical Director, NexLife · Board-certified in emergency medicine (American Board of Emergency Medicine) · NPI 1144260043

Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.

NexLife Medical TeamWrites and updates NexLife’s guides

Makers’ prices and TrumpRx.gov listings checked November 1, 2026; FDA patent data (the Orange Book), October 22, 2026.

  • How we checked. Every price and date here comes from the drugmaker, the government or the FDA, read on November 1, 2026 (the White House fact sheet and the FDA’s Orange Book on October 22, 2026): LillyDirect and Lilly’s terms, Lilly’s and Novo Nordisk’s news releases, NovoCare’s Wegovy prices, TrumpRx.gov, the White House, CMS and the FDA’s Orange Book. KFF explains Medicare’s net price. Compounded prices come from our GLP-1 price index, checked November 1, 2026. We list only announced changes, each with its date, and we don’t forecast prices.
  • Every fact, sourced. Each price and rule links to the page it comes from.
  • How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
  • Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.

Paying less elsewhere? We match it.†

You know what’s announced. Next: a 3-minute check.

A licensed provider reviews your health history and decides if compounded tirzepatide is right for you. $139 a month on the 12-month plan, or $169 month to month, at every dose.

Check my eligibilityPrefer semaglutide? $119/mo on 12 months
Call (949) 818-8000Text us

4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified

Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.

  1. 1
    Tell us about you

    Start online with your health history.

  2. 2
    A licensed provider decides

    Online, following your state’s rules. You’re prescribed only if treatment is right for you.

  3. 3
    We ship it, then stay with you

    Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.

Sources

  1. LillyDirect: Zepbound self-pay prices (KwikPen and vials). Checked November 1, 2026.
  2. Eli Lilly: Zepbound full terms and conditions (Self Pay Journey Program and savings cards). Read November 1, 2026.
  3. LillyDirect: Foundayo self-pay prices. Checked November 1, 2026.
  4. LillyDirect: Mounjaro self-pay prices. Checked November 1, 2026.
  5. Eli Lilly: How much should I expect to pay for Zepbound? (list price). Read November 1, 2026.
  6. Eli Lilly: Lilly lowers the price of Zepbound single-dose vials (December 1, 2025). Read November 1, 2026.
  7. Eli Lilly: Lilly and U.S. government agree to expand access to obesity medicines (November 6, 2025). Read November 1, 2026.
  8. Eli Lilly: Zepbound now available in multi-dose KwikPen (February 23, 2026). Read November 1, 2026.
  9. Eli Lilly: FDA approves Foundayo (orforglipron) (April 1, 2026). Read November 1, 2026.
  10. Eli Lilly: Retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026). Read November 1, 2026.
  11. The White House: Fact sheet on Most-Favored-Nation pricing, with the Eli Lilly and Novo Nordisk agreements (November 6, 2025). Read October 22, 2026.
  12. TrumpRx.gov: Zepbound vial. Checked November 1, 2026.
  13. TrumpRx.gov: Zepbound KwikPen. Checked November 1, 2026.
  14. TrumpRx.gov: Foundayo. Checked November 1, 2026.
  15. TrumpRx.gov: Wegovy pen. Checked November 1, 2026.
  16. TrumpRx.gov: Wegovy pill. Checked November 1, 2026.
  17. Novo Nordisk: What to pay for Wegovy. Checked November 1, 2026.
  18. Novo Nordisk: Introductory self-pay offer for Wegovy and Ozempic (November 17, 2025). Read November 1, 2026.
  19. Novo Nordisk: Wegovy pill now available (January 5, 2026). Read November 1, 2026.
  20. Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). Read November 1, 2026.
  21. Novo Nordisk: Files for FDA approval of CagriSema (December 18, 2025). Read November 1, 2026.
  22. Novo Nordisk: Company announcement on REDEFINE 4 and the CagriSema FDA timeline (February 23, 2026), SEC Form 6-K. Read November 1, 2026.
  23. FDA: Novel drug approvals for 2026. Checked November 1, 2026.
  24. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026). Read November 1, 2026.
  25. FDA Orange Book: Zepbound (NDA 217806) patents and exclusivity. Checked October 22, 2026.
  26. FDA Orange Book: Mounjaro (NDA 215866) patents and exclusivity. Checked October 22, 2026.
  27. CMS: Medicare GLP-1 Bridge. Read November 1, 2026.
  28. CMS: BALANCE Model. Read November 1, 2026.
  29. CMS: Medicare drug price negotiation, negotiated prices for 2027. Read November 1, 2026.
  30. CMS: Medicare drug price negotiation, selected drugs for 2028. Read November 1, 2026.
  31. KFF: What to know about the BALANCE Model and the Medicare GLP-1 Bridge (updated May 11, 2026). Read November 1, 2026.
  32. NexLife: GLP-1 price index. Compounded prices checked November 1, 2026.
  33. NexLife: pricing, every plan.